UNSPSC 51421701: Corticorelin ovine triflutate

This classification denotes a crh gene with the molecular formula C208H344N60O63S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 305OE8862Y, chemically known as l-alaninamide, l-seryl-l-glutaminyl-l-alpha-glutamyl-l-prolyl-l-prolyl-l-isoleucyl-l-seryl-l-leucyl-l-alpha-aspartyl-l-leucyl-l-threonyl-l-phenylalanyl-l-histidyl-l-leucyl-l-leucyl-l-arginyl-l-alpha-glutamyl-l-valyl-l-leucyl-l-alpha-glutamyl-l-methionyl-l-thronyl-l-lysyl-l-alanyl-l-alpha-aspartyl-l-glutaminyl-l-leucyl-l-alanyl-l-glutaminyl-l-glutaminyl-l-alanyl-l-histidyl-l-seryl-l-asparaginyl-l-arginyl-l-lysyl-l-leucyl-l-leucyl-l-alpha-aspartyl-l-isoleucyl- but generally known as corticorelin, which bears US NIH Compound Identifier 16132344.

UNSPSC 51421701 Corticorelin ovine triflutate is a Commodity code that shows a significant mismatch between its nominal pharmaceutical scope and the recent state and local opportunities posted under it. The code's abstract description — a specific synthetic hormone used in diagnostic testing — bears no relation to the work actually being solicited by state and local jurisdictions. Recent postings under this code involve procurement of naloxone (opioid antagonist medication) and drug deactivation systems, along with exploratory market research into direct-to-manufacturer prescription fulfillment models. The actual buying pattern reflects health and human services procurement across county health departments and state pharmacy benefit programs, not the endocrine diagnostic agent the code nominally describes.

Issuing bodies include county-level health agencies and state-level health and human services commissions. Recent activity centers on Florida and Texas, with Seminole County, Florida posting an IFB on June 30, 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 drug deactivation systems annually, to be delivered quarterly to the Seminole County Community Health Building, and the Texas Health and Human Services Commission issuing an RFI on April 3, 2026 regarding direct-to-manufacturer prescription programs for self-insured employee and state agency health plans. The code shows limited recent activity overall, and the mismatch between the code's intended pharmaceutical classification and the health-systems work actually posted under it suggests either tagging error or category drift within state procurement systems. Business development professionals should verify opportunity alignment independently rather than relying on the code classification alone.